PubRank

H Derendorf

Author PubWeight™ 88.00‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Grapefruit-drug interactions: can interactions with drugs be avoided? J Clin Pharmacol 2006 1.82
2 Pharmacokinetics and bioavailability of quercetin glycosides in humans. J Clin Pharmacol 2001 1.57
3 AUIC--a general target for the optimization of dosing regimens of antibiotics? Ann Pharmacother 1996 1.51
4 Pharmacokinetic characterization and tissue distribution of the new glucocorticoid soft drug loteprednol etabonate in rats and dogs. J Pharm Sci 1992 1.45
5 Systemic bioavailability of inhaled steroids: the importance of appropriate and comparable methodology. Eur Respir J 2001 1.43
6 Microdialysis in peripheral tissues. Adv Drug Deliv Rev 2000 1.35
7 Microdialysis. A novel tool for clinical studies of anti-infective agents. Eur J Clin Pharmacol 2001 1.34
8 Pharmacokinetics and pharmacodynamics of glucocorticoid suspensions after intra-articular administration. Clin Pharmacol Ther 1986 1.32
9 Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling. Int J Clin Pharmacol Ther 1997 1.25
10 Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration. Eur J Clin Pharmacol 1998 1.17
11 Pharmacokinetic and pharmacodynamic changes in the elderly. Clinical implications. Clin Pharmacokinet 1998 1.17
12 Pharmacokinetic/pharmacodynamic aspects of aerosol therapy using glucocorticoids as a model. J Clin Pharmacol 1997 1.16
13 Population pharmacokinetics of intramuscular quinine in children with severe malaria. Antimicrob Agents Chemother 2001 1.04
14 Pharmacokinetics of iron(III)-hydroxide sucrose complex after a single intravenous dose in healthy volunteers. Arzneimittelforschung 1996 1.04
15 Penetration of cefaclor into the interstitial space fluid of skeletal muscle and lung tissue in rats. Pharm Res 2001 1.02
16 A combined in vivo pharmacokinetic-in vitro pharmacodynamic approach to simulate target site pharmacodynamics of antibiotics in humans. J Antimicrob Chemother 2000 0.99
17 Pharmacokinetic-pharmacodynamic modeling of the antibiotic effect of piperacillin in vitro. Pharm Res 1996 0.99
18 Determination of free interstitial concentrations of piperacillin-tazobactam combinations by microdialysis. J Antimicrob Chemother 1998 0.98
19 Dynamic modeling of cortisol reduction after inhaled administration of fluticasone propionate. J Clin Pharmacol 1996 0.98
20 Gender differences in pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ther 1999 0.97
21 Comparison of plasma and free tissue levels of ceftriaxone in rats by microdialysis. J Pharm Sci 1997 0.97
22 A sensitive LC-MS/MS method for the quantification of fluticasone propionate in human plasma. J Pharm Biomed Anal 2000 0.95
23 Pharmacokinetics and pharmacodynamics of tilmicosin in sheep and cattle. J Vet Pharmacol Ther 1998 0.94
24 Pharmacokinetics and bioavailability of the flavonol quercetin in humans. Int J Clin Pharmacol Ther 1999 0.94
25 Bioavailability and pharmacokinetics of caffeoylquinic acids and flavonoids after oral administration of Artichoke leaf extracts in humans. Phytomedicine 2005 0.94
26 Pharmacokinetic-pharmacodynamic modelling of the in vitro antiinfective effect of piperacillin-tazobactam combinations. Int J Clin Pharmacol Ther 1997 0.93
27 Dependency of cortisol suppression on the administration time of inhaled corticosteroids. J Clin Pharmacol 1997 0.93
28 A pharmacokinetic/pharmacodynamic approach to predict the cumulative cortisol suppression of inhaled corticosteroids. J Pharmacokinet Biopharm 1999 0.92
29 Determination of free extracellular concentrations of piperacillin by microdialysis. J Pharm Sci 1996 0.92
30 An interactive algorithm for the assessment of cumulative cortisol suppression during inhaled corticosteroid therapy. AAPS PharmSci 2000 0.92
31 Pharmacokinetics of triamcinolone acetonide and its phosphate ester. Eur J Clin Pharmacol 1985 0.92
32 Simultaneous measurement of cortisol in serum and saliva after different forms of cortisol administration. Clin Chem 1992 0.90
33 Biowaiver monographs for immediate release solid oral dosage forms: prednisolone. J Pharm Sci 2007 0.89
34 Single-dose and steady-state pharmacokinetic and pharmacodynamic evaluation of therapeutically clinically equivalent doses of inhaled fluticasone propionate and budesonide, given as Diskus or Turbohaler dry-powder inhalers to healthy subjects. J Clin Pharmacol 2001 0.89
35 Interpretation of absorption rate data for inhaled fluticasone propionate obtained in compartmental pharmacokinetic modeling. Int J Clin Pharmacol Ther 2005 0.88
36 Rapid chromatographic determination of cefotaxime and its metabolite in biological fluids. J Chromatogr 1985 0.88
37 Kinetics of methylprednisolone and its hemisuccinate ester. Clin Pharmacol Ther 1985 0.87
38 Disposition of cefotaxime and its desacetyl metabolite in morbidly obese male and female subjects. Ther Drug Monit 1986 0.87
39 Pharmacokinetics of methylprednisolone and prednisolone after single and multiple oral administration. J Clin Pharmacol 1997 0.86
40 Desensitization of brain opiate receptor mechanisms by gonadal steroid treatments that stimulate luteinizing hormone secretion. Endocrinology 1988 0.85
41 Pharmacokinetics of dexamethasone and its phosphate ester. Biopharm Drug Dispos 1987 0.85
42 Pharmacokinetic-pharmacodynamic profile of systemic nitric oxide-synthase inhibition with L-NMMA in humans. Br J Clin Pharmacol 1999 0.85
43 HPLC determination of dexamethasone in human plasma and its application to an in vitro release study from endovascular stents. Pharmazie 2006 0.84
44 Pharmacokinetic/pharmacodynamic (PK/PD) evaluation of a once-daily treatment using ciprofloxacin in an extended-release dosage form. Infection 2005 0.84
45 Simultaneous assay of propranolol, diltiazem and metabolites of diltiazem in human plasma by liquid chromatography. J Pharm Biomed Anal 1990 0.84
46 Pharmacokinetic properties of beta-lactamase inhibitors. Int J Clin Pharmacol Ther 1999 0.84
47 Pharmacokinetics of dichloroacetate in adult patients with lactic acidosis. J Clin Pharmacol 1997 0.84
48 Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone. Pharm Res 1995 0.84
49 Population pharmacokinetics of steady-state carbamazepine in Egyptian epilepsy patients. J Clin Pharm Ther 2011 0.83
50 Local treatment of respiratory infections with antibiotics. Drug Intell Clin Pharm 1987 0.83
51 Relationship between serum and free interstitial concentrations of cefodizime and cefpirome in muscle and subcutaneous adipose tissue of healthy volunteers measured by microdialysis. J Clin Pharmacol 1997 0.83
52 A pharmacokinetic/pharmacodynamic approach to predict total prednisolone concentrations in human plasma. J Pharmacokinet Pharmacodyn 2007 0.83
53 Population pharmacokinetic/pharmacodynamic modeling of cetrorelix, a novel LH-RH antagonist, and testosterone in rats and dogs. Pharm Res 2000 0.82
54 Evaluation of a brain-targeting zidovudine chemical delivery system in dogs. Antimicrob Agents Chemother 1997 0.82
55 Pharmacokinetics of intravenous immunoglobulin (Gammagard) in bone marrow transplant patients. J Clin Pharmacol 1991 0.82
56 Pharmacokinetics and pharmacodynamics of prednisolone after intravenous and oral administration. Int J Clin Pharmacol Ther Toxicol 1992 0.82
57 A review of the effects of chronic exercise and physical fitness level on resting pharmacokinetics. Int J Clin Pharmacol Ther 2003 0.81
58 Changes in cortical evoked potentials as correlates of the efficacy of weak analgesics. Pain 1982 0.81
59 Pharmacokinetic and pharmacodynamic evaluation of triamcinolone acetonide after intravenous, oral, and inhaled administration. J Clin Pharmacol 1995 0.81
60 Pharmacokinetics and pharmacodynamics of dexamethasone sodium-m-sulfobenzoate (DS) after intravenous and intramuscular administration: a comparison with dexamethasone phosphate (DP). J Clin Pharmacol 2001 0.81
61 Pharmacokinetic/pharmacodynamic evaluation of systemic effects of flunisolide after inhalation. J Clin Pharmacol 1997 0.81
62 Soft cannabinoid analogues as potential anti-glaucoma agents. Pharmazie 2002 0.81
63 Pharmacokinetic/pharmacodynamic modeling of cortisol suppression after oral administration of fluocortolone. J Clin Pharmacol 1996 0.80
64 Influence of the Duffy antigen on pharmacokinetics and pharmacodynamics of recombinant monocyte chemoattractant protein (MCP-1, CCL-2) in vivo. Int J Immunopathol Pharmacol 2009 0.80
65 Effect of fat distribution on the pharmacokinetics of cortisol in obesity. Int J Clin Pharmacol Ther 1998 0.80
66 Intravenous and oral pharmacokinetic evaluation of a 2-hydroxypropyl-beta-cyclodextrin-based formulation of carbamazepine in the dog: comparison with commercially available tablets and suspensions. J Pharm Sci 1997 0.79
67 Pharmacokinetic-pharmacodynamic modeling of testosterone and luteinizing hormone suppression by cetrorelix in healthy volunteers. J Clin Pharmacol 2000 0.79
68 High-performance liquid chromatographic assay of a central nervous system (CNS)-directed estradiol chemical delivery system and its application after intravenous administration to rats. Pharm Res 1988 0.79
69 A selective HPLC/RIA for the determination of budesonide. J Pharm Biomed Anal 1998 0.79
70 [Quantification of the attenuation of pain sensation through evoked potentials after the application of mild analgesics (author's transl)]. EEG EMG Z Elektroenzephalogr Elektromyogr Verwandte Geb 1980 0.79
71 Non-compartmental analysis of pharmacokinetic data after multiple intravenous and oral administration. Pharmazie 1997 0.79
72 Pulmonary targeting of liposomal triamcinolone acetonide phosphate. Pharm Res 1996 0.79
73 Evoked potentials as objective parameters for the analgesic response of weak analgesics. Adv Neurol 1982 0.79
74 Improved delivery through biological membranes. XXXL: Solubilization and stabilization of an estradiol chemical delivery system by modified beta-cyclodextrins. J Pharm Sci 1988 0.79
75 [Pharmacokinetics and pharmacodynamics of prednisolone following extremely high dosage as prednisolone hemisuccinate]. Arzneimittelforschung 1987 0.79
76 Pharmacokinetic modelling of serum and bronchial concentrations for clarithromycin and telithromycin, and site-specific pharmacodynamic simulation for their dosages. J Clin Pharm Ther 2014 0.78
77 Pitfalls in pharmacokinetic multicompartment analysis. J Pharmacokinet Biopharm 1998 0.78
78 Comparison of talinolol and atenolol effects on blood pressure in relation to lipid and glucose metabolic parameters. Results from the TALIP study. Int J Clin Pharmacol Ther 2003 0.78
79 Increased erythrocyte and protein binding of codeine in patients with sickle cell disease. J Pharm Sci 1993 0.78
80 Pharmacokinetic/pharmacodynamic evaluation of the NHE inhibitor eniporide. J Clin Pharmacol 2001 0.78
81 Plasma and dermal pharmacokinetics of terpinen-4-ol in rats following intravenous administration. Pharmazie 2013 0.78
82 Pharmacokinetics and pharmacodynamics of enantiomers of ibuprofen and flurbiprofen after oral administration. Int J Clin Pharmacol Ther 1997 0.78
83 Pharmacokinetics of diclofenac sodium after intramuscular administration in combination with triamcinolone acetate. Eur J Clin Pharmacol 1986 0.77
84 Relationship between saliva levels of metamizol metabolites, bioavailability and analgesic efficacy. Arzneimittelforschung 1983 0.77
85 Impact of tazobactam pharmacokinetics on the antimicrobial effect of piperacillin-tazobactam combinations. Int J Antimicrob Agents 2004 0.77
86 Evolution of pharmacokinetics and pharmacokinetic/dynamic correlations during the 20th century. J Clin Pharmacol 2000 0.77
87 Population pharmacokinetics of digoxin in Korean patients. Int J Clin Pharmacol Ther 2000 0.77
88 Current concepts in pharmacokinetics and their implications for clinical medicine. Wien Klin Wochenschr 2001 0.77
89 Pharmacokinetics of morphine and its surrogates. VII: High-performance liquid chromatographic analyses and pharmacokinetics of methadone and its derived metabolites in dogs. J Pharm Sci 1985 0.77
90 Pharmacokinetic interaction between endogenous cortisol and exogenous corticosteroids. Pharmazie 1995 0.77
91 Pharmacokinetics of detirelix following intratracheal instillation and aerosol inhalation in the unanesthetized awake sheep. Pharm Res 1994 0.77
92 Mechanism-based PK/PD model for the lymphocytopenia induced by endogenous and exogenous corticosteroids. Int J Clin Pharmacol Ther 1999 0.77
93 Pharmacokinetics and rectal bioavailability of hydrocortisone acetate after single and multiple administration in healthy subjects and patients. J Clin Pharmacol 2001 0.76
94 Pharmacodynamic evaluation of codeine using tooth pulp evoked potentials. J Clin Pharmacol 1996 0.76
95 Clinical and pharmacological aspects of accidental triamcinolone acetonide overdosage: a case study. Neth J Med 2000 0.76
96 Pharmacokinetics of cefpodoxime in plasma and subcutaneous fluid following oral administration of cefpodoxime proxetil in male beagle dogs. J Vet Pharmacol Ther 2011 0.76
97 Evaluation of free tissue concentrations of fleroxacin after oral administration. Pharm Res 1990 0.76
98 Population pharmacokinetics of methylprednisolone in accident victims with spinal cord injury. Int J Clin Pharmacol Ther 2004 0.75
99 Electrochemical chromatographic determinations of morphine antagonists in biological fluids, with applications. J Pharm Sci 1984 0.75
100 Pharmacokinetic and pharmacodynamic modeling of cetrorelix, an LH-RH antagonist, after subcutaneous administration in healthy premenopausal women. Clin Pharmacol Ther 2000 0.75
101 A selective LC/RIA for dexamethasone and its prodrug dexamethasone-21-isonicotinate in biological fluids. J Pharm Biomed Anal 1991 0.75
102 The influence of formulation on the dissolution profile of diclofenac sodium tablets. Drug Dev Ind Pharm 2006 0.75
103 Data warehousing. Int J Clin Pharmacol Ther 2002 0.75
104 Sensitive liquid chromatography assay for the determination of amikacin in human plasma. J Pharm Biomed Anal 1991 0.75
105 In vitro recovery of triamcinolone acetonide in microdialysis. Pharmazie 2000 0.75
106 Pharmacokinetic evaluation of two ibuprofen-codeine combinations. Int J Clin Pharmacol Ther 1994 0.75
107 Prednicarbate after different forms of administration. Plasma levels of drug and metabolites and effects on endogenous cortisol levels in humans. Curr Probl Dermatol 1993 0.75
108 Simultaneous determination of glucocorticoid alcohols, their succinates and hydrocortisone in plasma. J Pharm Biomed Anal 1985 0.75
109 Biowaiver monographs for immediate release solid oral dosage forms: prednisone. J Pharm Sci 2007 0.75
110 Pharmacokinetics and dose linearity testing of methylprednisolone phosphate. Biopharm Drug Dispos 1989 0.75
111 Codeine disposition in sickle cell patients compared with healthy volunteers. J Clin Pharmacol 1993 0.75
112 Pharmacokinetics and rectal bioavailability of hydrocortisone acetate. J Pharm Sci 1991 0.75
113 A selective HPLC/RIA for dexamethasone and its prodrug dexamethasone-21-sulphobenzoate sodium in biological fluids. Biomed Chromatogr 1993 0.75
114 Pharmacokinetic profile of cefaclor. Int J Clin Pharmacol Ther 1997 0.75
115 Estimation of lithium clearance from routine clinical data in Egyptian bipolar patients. A population pharmacokinetic approach. Int J Clin Pharmacol Ther 2008 0.75
116 Coulometric high-performance liquid chromatographic analysis of morphine in biological fluids. J Pharm Sci 1986 0.75
117 Rapid analysis of ranitidine in biological fluids and determination of its erythrocyte partitioning. J Chromatogr 1986 0.75
118 Pharmacokinetics and pharmacodynamics of cloprednol. Int J Clin Pharmacol Ther 1996 0.75
119 A redox-based chemical delivery system that enhances estradiol distribution to the brain: disposition studies in the rat. Pharm Res 1991 0.75
120 Assessment of glucocorticoid lung targeting by ex-vivo receptor binding studies in rats. Pharm Res 1995 0.75
121 Pharmacokinetic-pharmacodynamic relationships for analgesics. Int J Clin Pharmacol Ther 1997 0.75
122 Pharmacokinetics of prednisolone after high doses of prednisolone hemisuccinate. Biopharm Drug Dispos 1986 0.75
123 Lack of clinically significant in vitro and in vivo interactions between ranitidine and sucralfate. J Pharm Sci 1986 0.75
124 High-performance liquid chromatographic assay and erythrocyte partitioning of fleroxacin, a new fluoroquinolone antibiotic. J Pharm Biomed Anal 1990 0.75
125 Cortical-evoked potentials and saliva levels as basis for the comparison of pure analgesics to analgesic combinations. Pharmacology 1982 0.75
126 KA 672-HCl, a neuronal activator against dementia: tolerability, safety, and preliminary pharmacokinetics after single and multiple oral doses in healthy male and female volunteers. J Clin Pharmacol 1998 0.75
127 Effect of high doses of glucocorticoids on the kinetics of human white blood cells in vivo. Med Klin (Munich) 1988 0.75
128 Comparative pharmacokinetics of methylprednisolone phosphate and hemisuccinate in high doses. Pharm Res 1988 0.75
129 Pharmacokinetics of ranitidine after partial gastrectomy in dogs. J Pharm Sci 1991 0.75
130 Theophylline absorption and gastric emptying after partial gastrectomy in dogs. J Pharm Sci 1990 0.75
131 Extent of drug absorption at the time of peak plasma concentration in an open one-compartment body model with first-order absorption. J Pharm Sci 1990 0.75
132 Erythrocyte binding of cephalosporins. J Pharm Pharmacol 1987 0.75
133 High-performance liquid chromatographic determination of conjugated estrogens in tablets. J Chromatogr 1988 0.75
134 Effects of truncal vagotomy and partial gastrectomy on the pharmacokinetics of propranolol enantiomers in dogs. J Pharm Sci 1990 0.75
135 [Problems of equivalency points during therapy with glucocorticoids. A comparison of the clinical pharmacokinetics and pharmacodynamics of prednisolone and methylprednisolone]. Dtsch Med Wochenschr 1994 0.75
136 HPLC analysis of buprenorphine in plasma and urine using coulometric detection. J Pharm Biomed Anal 1987 0.75
137 The lack of effect of aerobic exercise training on propranolol pharmacokinetics in young and elderly adults. J Clin Pharmacol 1995 0.75
138 Studies on the pharmacokinetics and metabolism of prednicarbate after cutaneous and oral administration. Skin Pharmacol 1993 0.75
139 Pharmacokinetic/pharmacodynamic model-based combination therapy approach to target antibiotic resistant populations emerged from ciprofloxacin exposure. Pharmazie 2010 0.75
140 High-performance liquid chromatographic assay of methadone, phencyclidine, and metabolites by postcolumn ion-pair extraction and on-line fluorescent detection of the counterion with applications. J Pharm Sci 1983 0.75
141 [Microdialysis for the determination of free drugs in tissues]. Pharm Unserer Zeit 1997 0.75
142 Computer-modulated patient-controlled analgesia. Preliminary evaluation of a prototype. Reg Anesth 1994 0.75
143 A redox-based system that enhances delivery of estradiol to the brain: pharmacokinetic evaluation in the dog. Pharm Res 1990 0.75
144 Simultaneous determination of propranolol and 4-hydroxypropranolol enantiomers after chiral derivatization using reversed-phase high-performance liquid chromatography. J Chromatogr 1990 0.75